Phenotypical and functional profiles of natural killer cells exhibiting matrix metalloproteinase-mediated CD16 cleavage after anti-HIV antibody-dependent activation

Clinical and Experimental Immunology

Volumn 181, Issue 2, 2015, Pages 275-285

  Tang, C C ^a   Isitman, G ^b   Bruneau, J ^c   Tremblay, C ^c   Bernard, N F ^b   Kent, S J ^a,d   Parsons, M S ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d MELBOURNE SEXUAL HEALTH CENTRE   (Australia)

Author keywords

AIDS; KIR3DL1; NK cell education

Indexed keywords

CD16 ANTIGEN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; ILOMASTAT; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DL1; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MATRIX METALLOPROTEINASE; ANTIBODY; FC RECEPTOR; FCGR3B PROTEIN, HUMAN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; HLA B ANTIGEN; HLA-BW4 ANTIGEN; KIR3DL1 PROTEIN, HUMAN; VIRUS RNA;

ANTIGEN EXPRESSION; ARTICLE; CELL ACTIVATION; CELL FUNCTION; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BLOOD; DISEASE COURSE; DRUG EFFECTS; GENE EXPRESSION; GENETICS; HISTOCOMPATIBILITY TEST; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; PATHOLOGY; PRIMARY CELL CULTURE; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION; VIROLOGY; VIRUS LOAD;

ANTIBODIES; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; DISEASE PROGRESSION; GENE EXPRESSION; GPI-LINKED PROTEINS; HISTOCOMPATIBILITY TESTING; HIV INFECTIONS; HIV-1; HLA-B ANTIGENS; HUMANS; IMMUNOPHENOTYPING; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MATRIX METALLOPROTEINASES; PHENOTYPE; PRIMARY CELL CULTURE; PROTEOLYSIS; RECEPTORS, IGG; RECEPTORS, KIR3DL1; RNA, VIRAL; SIGNAL TRANSDUCTION; VIRAL LOAD;

EID: 84948095470     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12593     Document Type: Article

References (30)

1. Hessell AJ, Hangartner L, Hunter M. et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007; 449:101-4.
2. Montefiori DC, Karnasuta C, Huang Y. et al. Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis 2012; 206:431-41.
3. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S. et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-20.
4. Haynes BF, Gilbert PB, McElrath MJ. et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012; 366:1275-86.
5. Tomaras GD, Ferrari G, Shen X. et al. Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc Natl Acad Sci USA 2013; 110:9019-24.
6. Mabuka J, Nduati R, Odem-Davis K, Peterson D, Overbaugh J. HIV-specific antibodies capable of ADCC are common in breastmilk and are associated with reduced risk of transmission in women with high viral loads. PLOS Pathog 2012; 8:e1002739.
7. Alpert MD, Harvey JD, Lauer WA. et al. ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge. PLOS Pathog 2012; 8:e1002890.
8. Lambotte O, Ferrari G, Moog C. et al. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS 2009; 23:897-906.
9. Wren LH, Chung AW, Isitman G. et al. Specific antibody-dependent cellular cytotoxicity responses associated with slow progression of HIV infection. Immunology 2013; 138:116-23.
10. Banks ND, Kinsey N, Clements J, Hildreth JE. Sustained antibody-dependent cell-mediated cytotoxicity (ADCC) in SIV-infected macaques correlates with delayed progression to AIDS. AIDS Res Hum Retroviruses 2002; 18:1197-205.
11. Brenner BG, Gryllis C, Wainberg MA. Role of antibody-dependent cellular cytotoxicity and lymphokine-activated killer cells in AIDS and related diseases. J Leukoc Biol 1991; 50:628-40.
12. Jia M, Li D, He X. et al. Impaired natural killer cell-induced antibody-dependent cell-mediated cytotoxicity is associated with human immunodeficiency virus-1 disease progression. Clin Exp Immunol 2013; 171:107-16.
13. Tyler DS, Stanley SD, Nastala CA. et al. Alterations in antibody-dependent cellular cytotoxicity during the course of HIV-1 infection. Humoral and cellular defects. J Immunol 1990; 144:3375-84.
14. Grzywacz B, Kataria N, Verneris MR. CD56(dim)CD16(+) NK cells downregulate CD16 following target cell induced activation of matrix metalloproteinases. Leukemia 2007; 21:356-9.
15. Jewett A, Cavalcanti M, Giorgi J, Bonavida B. Concomitant killing in vitro of both gp120-coated CD4+ peripheral T lymphocytes and natural killer cells in the antibody-dependent cellular cytotoxicity (ADCC) system. J Immunol 1997; 158:5492-500.
16. Parsons MS, Tang CC, Jegaskanda S. et al. Anti-HIV antibody-dependent activation of NK cells impairs NKp46 expression. J Immunol 2014; 192:308-15.
17. Romee R, Foley B, Lenvik T. et al. NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17). Blood 2013; 121:3599-608.
18. Fauriat C, Long EO, Ljunggren HG, Bryceson YT. Regulation of human NK-cell cytokine and chemokine production by target cell recognition. Blood 2010; 115:2167-76.
19. Anfossi N, Andre P, Guia S. et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity 2006; 25:331-42.
20. Parsons MS, Wren L, Isitman G. et al. HIV infection abrogates the functional advantage of natural killer cells educated through KIR3DL1/HLA-Bw4 interactions to mediate anti-HIV antibody-dependent cellular cytotoxicity. J Virol 2012; 86:4488-95.
21. Parsons MS, Zipperlen K, Gallant M, Grant M. Killer cell immunoglobulin-like receptor 3DL1 licenses CD16-mediated effector functions of natural killer cells. J Leukoc Biol 2010; 88:905-12.
22. Boulet S, Sharafi S, Simic N. et al. Increased proportion of KIR3DS1 homozygotes in HIV-exposed uninfected individuals. AIDS 2008; 22:595-9.
23. Boulet S, Kleyman M, Kim JY. et al. A combined genotype of KIR3DL1 high expressing alleles and HLA-B*57 is associated with a reduced risk of HIV infection. AIDS 2008; 22:1487-91.
24. Trundley A, Frebel H, Jones D, Chang C, Trowsdale J. Allelic expression patterns of KIR3DS1 and 3DL1 using the Z27 and DX9 antibodies. Eur J Immunol 2007; 37:780-7.
25. Hu PF, Hultin LE, Hultin P. et al. Natural killer cell immunodeficiency in HIV disease is manifest by profoundly decreased numbers of CD16+CD56+ cells and expansion of a population of CD16dimCD56- cells with low lytic activity. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10:331-40.
26. Liu Q, Sun Y, Rihn S. et al. Matrix metalloprotease inhibitors restore impaired NK cell-mediated antibody-dependent cellular cytotoxicity in human immunodeficiency virus type 1 infection. J Virol 2009; 83:8705-12.
27. Lichtfuss GF, Cheng WJ, Farsakoglu Y. et al. Virologically suppressed HIV patients show activation of NK cells and persistent innate immune activation. J Immunol 2012; 189:1491-9.
28. Khayat D, Soubrane C, Andrieu JM. et al. Changes of soluble CD16 levels in serum of HIV-infected patients: correlation with clinical and biologic prognostic factors. J Infect Dis 1990; 161:430-5.
29. Autran B, Descours B, Bacchus C. Immune control of HIV-1 reservoirs. Curr Opin HIV AIDS 2013; 8:204-10.
30. Kent SJ, Reece JC, Petravic J. et al. The search for an HIV cure: tackling latent infection. Lancet Infect Dis 2013; 13:614-21.